The Manufacturers Life Insurance Company Takes $6.12 Million Position in Dianthus Therapeutics, Inc. $DNTH

Key Points

• The Manufacturers Life Insurance Company acquired 62,829 shares of Dianthus Therapeutics, worth approximately $6.12 million, giving it a 0.11% stake. Institutional investors collectively own 47.53% of DNTH.
• Analyst sentiment remains generally positive: the stock carries a “Moderate Buy” consensus rating, with an average price target of $124.27; Truist raised its target to $128 and maintained a “Buy” rating.
• DNTH recently traded at $105.61 after reporting a quarterly loss of $0.90 per share, worse than the expected $0.85 loss, though revenue of $0.76 million exceeded estimates. Insiders sold approximately $27.2 million of shares over the past 90 days.

The Manufacturers Life Insurance Company acquired a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 62,829 shares of the company's stock, valued at approximately $6,125,000. The Manufacturers Life Insurance Company owned approximately 0.11% of Dianthus Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of DNTH. PNC Financial Services Group Inc. boosted its stake in Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company's stock valued at $3,135,000 after buying an additional 139 shares in the last quarter. First Horizon Corp bought a new stake in Dianthus Therapeutics in the first quarter worth about $32,000. Virtus Investment Advisers LLC raised its position in Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company's stock worth $260,000 after acquiring an additional 416 shares in the last quarter. Royal Bank of Canada lifted its holdings in Dianthus Therapeutics by 36.9% in the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company's stock valued at $82,000 after acquiring an additional 542 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock valued at $280,000 after acquiring an additional 618 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on DNTH shares. Wall Street Zen raised shares of Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Truist Financial raised their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Guggenheim restated a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $124.27.

Insiders Place Their Bets

In related news, Director Anne Mcgeorge sold 7,750 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the transaction, the director directly owned 1,250 shares of the company's stock, valued at approximately $136,262.50. The trade was a 86.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Adam M. Veness sold 16,167 shares of the company's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the completion of the transaction, the senior vice president owned 3,833 shares in the company, valued at approximately $423,086.54. This represents a 80.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 260,554 shares of company stock valued at $27,211,775 over the last ninety days. Insiders own 3.02% of the company's stock.

Dianthus Therapeutics Trading Down 0.2%

NASDAQ:DNTH opened at $105.61 on Tuesday. The business's fifty day moving average price is $103.96 and its 200 day moving average price is $87.71. The firm has a market capitalization of $5.77 billion, a price-to-earnings ratio of -25.45 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 1-year low of $22.81 and a 1-year high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source